Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 21, 2002 FBO #0262
SOLICITATION NOTICE

68 -- Contrast Agent

Notice Date

8/19/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20112-NG
 

Response Due

9/3/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Radiation Biology Branch (RBB) intends to procure Contrast Agent; catalog number OXo63 (EPR-Line substance, 92 grams), for Phillips Overhauser Enhanced Magnetic Resonance Imaging (OMRI) for Studying Tumor Physiology from Amersham Health, R&D AB Medeon, SE-205 12, Malmo Sweden. The supplies and services herein are being prepared in accordance with the format in FAR Part 12. The North American Industry Classification System code is 422210 and the business size standard is 100 employees. The Radiation Research Branch has a research interest in the treatment of malignant tumors by non-surgical modalities, like radiation or chemotherapy, which may be influenced both by the genetic properties of the tumor cells and epigenetic factors of the tumor micromilieu. The proposed research involves the use of Overhauser Enhanced Magnetic Resonance Imaging (OMRI) to obtain functional/physiologic information in tumors using, which treatment regimens will be adjusted depending on the oxygen status of the tumors and appropriate therapies can be instituted. While extensive research is presently ongoing to develop gene therapy strategies targeted to tumor cells, the development of therapeutic regimens to exploit the physiological differences between normal and malignant tissue might also provide options for improved treatment. Some of the physiological differences between normal tissue and tumors include oxygen status, redox status, and intracellular pH. These differences, at least in part, can result from the physical architecture of the tumors with compromised blood supply. Methods that can detect subtle differences in the above physiological parameters would greatly aid in devising appropriate treatment strategies. Redox status and tissue pO2 are two factors, which are hypothesized to be different in normal and malignant tissues. Techniques that enable rapid and noninvasive measurements of these two parameters in individual patients, therefore, would extend our knowledge and clinical acumen. This technique can be effectively used to gain information regarding tumor physiology. This is relevant to several ongoing preclinical and clinical studies being conducted at NCI. There are two components in this technique: 1) The low field OMRI scanner; 2) Suitable contrast agent which can provide optimal Overhauser Enhancements. NCI has a custom built OMRI scanner from Philips Medical Systems. The contrast agent is a crucial aspect of this study and the requirements in terms of amount is in range of 100 grams/year. Information obtained from OMRI is unique with respect to the physiological information it provides which can be co-registered with standard MRI data. Therefore it becomes now possible to characterize a tissue on the basis of important functional information such as tissue pO2, which would otherwise be not possible by most radiological techniques. The non-invasive nature of OMRI in providing such information holds significant promise in clinical radiology, particularly in tumor physiology characterization by non-invasive means and develops optimal treatment protocols. Current methods to characterize tumor pO2 to decide the radiation treatment planning are highly invasive leading to issues regarding patient comfort and compliance making such studies difficult. Amersham Health Biotech is the only known source to the NCI that can provide the contrast agents. The Phillips OMRI is the only machine, which can provide readings as such a low level (10Mt). This technique has the potential of providing both functional as well as physiological information using spin probe tracer using the low field OMRI. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain sufficient detail to allow the NCI to determine if the party can fully meet the Government needs. Capability statements must be received in the contracting office no later than 1 PM EDT (local Washington DC time) on September 3, 2002. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent, via electronic mail at holdcram@exchange.nih.gov or by fax (301) 402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00143831-W 20020821/020819213232 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |